Cardiotoxicity of breast cancer drug treatments

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2025-03-15 DOI:10.1016/j.tranon.2025.102352

Maria Haque , Nehal Atallah , Rodhan Patke , Anna E Harris , Corinne L Woodcock , Dhruvika Varun , Rachel L Thompson , Jorja Jackson-Oxley , Cyntholia H Okui , Alexander Dean , Mansour Alsaleem , Emad Rakha , Sheeba Irshad , Melissa B Davis , Jennie N Jeyapalan , Nigel P Mongan , Catrin S Rutland

{"title":"Cardiotoxicity of breast cancer drug treatments","authors":"Maria Haque , Nehal Atallah , Rodhan Patke , Anna E Harris , Corinne L Woodcock , Dhruvika Varun , Rachel L Thompson , Jorja Jackson-Oxley , Cyntholia H Okui , Alexander Dean , Mansour Alsaleem , Emad Rakha , Sheeba Irshad , Melissa B Davis , Jennie N Jeyapalan , Nigel P Mongan , Catrin S Rutland","doi":"10.1016/j.tranon.2025.102352","DOIUrl":null,"url":null,"abstract":"<div><div>Breast cancer (BC) is a leading cause of cancer-related mortality among women worldwide. BC is regarded as a systemic disease. Consequently, the majority of BC patients undergo systemic therapy to reduce the risk of distant metastasis (DM) and associated mortality. Although systemic therapies improve patients’ outcome, they are associated with significant side effects, particularly cardiotoxicity and cardiovascular complications. Such side effects vary significantly in severity and duration. Cardiotoxicity may remain undetected for years post-treatment until the symptoms of heart failure (HF) present in the patient, which can reduce life expectancy, quality of life, and even lead to death. Therefore, it is vital to investigate the cardiotoxic and cardiovascular risks of BC treatment regimens to identify patients who would benefit most from cardiac monitoring. As it stands, cardiotoxicity is reported from individual studies or for selected drug therapies only. This review fulfils a gap in the literature by combining clinical studies of cardiotoxicity together from clinical trial data published on clinicaltrials.gov.uk.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"55 ","pages":"Article 102352"},"PeriodicalIF":5.0000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S193652332500083X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer (BC) is a leading cause of cancer-related mortality among women worldwide. BC is regarded as a systemic disease. Consequently, the majority of BC patients undergo systemic therapy to reduce the risk of distant metastasis (DM) and associated mortality. Although systemic therapies improve patients’ outcome, they are associated with significant side effects, particularly cardiotoxicity and cardiovascular complications. Such side effects vary significantly in severity and duration. Cardiotoxicity may remain undetected for years post-treatment until the symptoms of heart failure (HF) present in the patient, which can reduce life expectancy, quality of life, and even lead to death. Therefore, it is vital to investigate the cardiotoxic and cardiovascular risks of BC treatment regimens to identify patients who would benefit most from cardiac monitoring. As it stands, cardiotoxicity is reported from individual studies or for selected drug therapies only. This review fulfils a gap in the literature by combining clinical studies of cardiotoxicity together from clinical trial data published on clinicaltrials.gov.uk.

Abstract Image

查看原文本刊更多论文

乳腺癌（BC）是全球妇女因癌症死亡的主要原因。乳腺癌被认为是一种全身性疾病。因此，大多数乳腺癌患者都要接受全身治疗，以降低远处转移（DM）的风险和相关死亡率。虽然全身治疗可改善患者的预后，但也会产生明显的副作用，尤其是心脏毒性和心血管并发症。这些副作用的严重程度和持续时间差异很大。心脏毒性可能在治疗后数年仍未被发现，直到患者出现心力衰竭（HF）症状，从而缩短预期寿命，降低生活质量，甚至导致死亡。因此，研究 BC 治疗方案的心脏毒性和心血管风险以确定哪些患者最受益于心脏监测至关重要。目前，仅有个别研究或特定药物疗法报告了心脏毒性。本综述将临床试验数据中有关心脏毒性的临床研究与在 clinicaltrials.gov.uk 上公布的临床试验数据相结合，填补了文献中的空白。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.